scholarly journals Diabetic kidney disease: new clinical and therapeutic issues. Joint position statement of the Italian Diabetes Society and the Italian Society of Nephrology on “The natural history of diabetic kidney disease and treatment of hyperglycemia in patients with type 2 diabetes and impaired renal function”

2019 ◽  
Vol 33 (1) ◽  
pp. 9-35 ◽  
Author(s):  
Giuseppe Pugliese ◽  
◽  
Giuseppe Penno ◽  
Andrea Natali ◽  
Federica Barutta ◽  
...  

Abstract Aims This joint document of the Italian Diabetes Society and the Italian Society of Nephrology reviews the natural history of diabetic kidney disease (DKD) in the light of the recent epidemiological literature and provides updated recommendations on anti-hyperglycemic treatment with non-insulin agents. Data Synthesis Recent epidemiological studies have disclosed a wide heterogeneity of DKD. In addition to the classical albuminuric phenotype, two new albuminuria-independent phenotypes have emerged, i.e., “nonalbuminuric renal impairment” and “progressive renal decline”, suggesting that DKD progression toward end-stage kidney disease (ESKD) may occur through two distinct pathways, albuminuric and nonalbuminuric. Several biomarkers have been associated with decline of estimated glomerular filtration rate (eGFR) independent of albuminuria and other clinical variables, thus possibly improving ESKD prediction. However, the pathogenesis and anatomical correlates of these phenotypes are still unclear. Also the management of hyperglycemia in patients with type 2 diabetes and impaired renal function has profoundly changed during the last two decades. New anti-hyperglycemic drugs, which do not cause hypoglycemia and weight gain and, in some cases, seem to provide cardiorenal protection, have become available for treatment of these individuals. In addition, the lowest eGFR safety thresholds for some of the old agents, particularly metformin and insulin secretagogues, have been reconsidered. Conclusions The heterogeneity in the clinical presentation and course of DKD has important implications for the diagnosis, prognosis, and possibly treatment of this complication. The therapeutic options for patients with type 2 diabetes and impaired renal function have substantially increased, thus allowing a better management of these individuals.

Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 443-P
Author(s):  
YOSHINORI KAKUTANI ◽  
MASANORI EMOTO ◽  
YUKO YAMAZAKI ◽  
KOKA MOTOYAMA ◽  
TOMOAKI MORIOKA ◽  
...  

2019 ◽  
Vol 95 (1) ◽  
pp. 178-187 ◽  
Author(s):  
Guozhi Jiang ◽  
Andrea On Yan Luk ◽  
Claudia Ha Ting Tam ◽  
Fangying Xie ◽  
Bendix Carstensen ◽  
...  

2021 ◽  
Vol 18 (3) ◽  
pp. 17-25
Author(s):  
Stoiţă Marcel ◽  
Popa Amorin Remus

Abstract The presence of albuminuria in patients with type 2 diabetes mellitus is a marker of endothelial dysfunction and also one of the criteria for diagnosing diabetic kidney disease. The present study aimed to identify associations between cardiovascular risk factors and renal albumin excretion in a group of 218 patients with type 2 diabetes mellitus. HbA1c values, systolic blood pressure, diastolic blood pressure were statistically significantly higher in patients with microalbuinuria or macroalbuminuria compared to patients with normoalbuminuria (p <0.01). We identified a statistically significant positive association between uric acid values and albuminuria, respectively 25- (OH)2 vitamin D3 deficiency and microalbuminuria (p <0.01).


2008 ◽  
Vol 11 (4) ◽  
pp. 988-991
Author(s):  
Robert C Atkins ◽  
Paul Zimmet

In 2003, the International Society of Nephrology and the International Diabetes Federation launched a booklet called “Diabetes in the Kidney: Time to act” [1] to highlight the global pandemic of type 2 diabetes and diabetic kidney disease. ration (PZ)


2021 ◽  
Author(s):  
Ning Zhang ◽  
Rui Fan ◽  
Jing Ke ◽  
Qinghua Cui ◽  
Dong ZHAO

Abstract BackgroundMicroalbuminuria is the main characteristic of Diabetic kidney disease (DKD), but it fluctuates greatly under the influence of blood glucose. Our aim was to establish some common clinical variables which could be easily collected to predict the risk of DKD in patients with type 2 diabetes. Methods and resultsWe build an artificial intelligence (AI) model to quantitively predict the risk of DKD based on the biomedical parameters from 1239 patients. An information entropy-based feature selection method was applied to screen out the risk factors of DKD. The dataset was divided with 4/5 into the training set and 1/5 into the test set. By using the selected risk factors, 5-fold cross-validation is applied to train the prediction model and it finally got AUC of 0.72 and 0.71 in the training set and test set respectively. In addition, we provide a method of calculating risk factors’ contribution for individuals to provide personalized guidance for treatment. We set up web-based application available on http://www.cuilab.cn/dkd for self-check and early warning. ConclusionsWe establish a feasible prediction model for DKD and suggest the degree of risk contribution of each indicator for each individual, which has certain clinical significance for early intervention and prevention.


Sign in / Sign up

Export Citation Format

Share Document